MRNA Nov 2023 180.000 call
| Previous close | 0.1300 |
| Open | 0.1300 |
| Bid | 0.0500 |
| Ask | 0.0600 |
| Strike | 180.00 |
| Expiry date | 2023-11-17 |
| Day's range | 0.1300 - 0.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | 420 |
Yahoo FinanceNext-generation mRNA vaccines will be easier to use: Moderna CEO
Moderna CEO Stéphane Bancel says the company is working on a vaccine formula and packaging that will make it easier to use mNRA technology.
- Yahoo Finance Video
Moderna CEO on combo Covid, flu vaccine moving to next trial phase
A lot of Americans are planning on getting both a flu shot and Covid booster this fall. But Moderna (MRNA) has been working on a combination flu and Covid vaccine, so patients only need to get one shot instead of two. The biotech company announced that the combination vaccine will be moving on to its final trial after positive results from its early-stage trial. The company is hoping to have regulatory approval for the shot in 2025. Moderna CEO Stéphane Bancel tells Yahoo Finance Live that when it comes to it's current Covid vaccine, there has been "strong demand." Bancel expects to continue to see sales of the Covid vaccine into 2025 and "re-acceleration of sales" when the combination vaccine launches. When it comes to the current updated Covid booster, Bancel thinks that pharmacy chains may have underestimated demand for the shot and how quickly people would want it. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
ZacksNovavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab
Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.
